The aim of this study was to evaluate the effects of comorbid subthreshold anxiety on the course and the treatment of Depressive Disorders.
Introduction
Patients with depressive disorders presenting with an insufficient number or an insufficient duration of symptoms to fulfil DSM criteria for Major Depressive Disorder (MDD), frequently have a significant impairment in global functioning. These patients have been described as suffering from subthreshold or subclinical depressive syndromes (Olfson et al., 1996; Sherbourne et al., 1994) . However, these clinical conditions show a course that usually leads to the occurrence of major mood episodes, thus suggesting the existence of a common pathophysiological substrate for subthresold and Major Depression.
Clinical trials pointed out that adults with subthreshold depressive symptoms report higher frequency of medical and psychiatric comorbidity (Coulehan et al., 1990) , more severe work dysfunctioning, more psychiatric visits (Skodol et al., 1994) , more suicide attempts (Johnson et al., 1992) , a higher risk to develop a MDD (Fava, 1999; Judd et al., 1998) , and an overall poorer functional status (Berkman et al., 1986) than individuals without these symptoms.
In addition, up to 90 % of patients suffering from MDD have clinically significant anxiety features and, accordingly, a high proportion of patients with anxiety disorders will experience depressive symptoms lifetime (Sartorius et al., 1996) .
Even though the presence of high baseline anxiety levels has not been widely considered a predictor of the antidepressant response (Tollefson et al., 1994) , a comorbid anxiety disorder has been shown to determine a worse course for MDD (Altamura et al., 2003) . In particular, this comorbidity pattern is associated with longer episodes of illness, increased chronicization risk, increased substance abuse, a longer latency of the pharmacological response (Clayton et al., 1991) , significant functional impairment (Lecrubier and Ustun, 1998) , increased symptoms severity (Van Balkom et al., 2000) , and higher suicidal risk (Fawcett, 1990) .
In the clinical practice the co-occurence of depressive and anxiety symptoms is observed at different levels of severity, varying from comorbid fullsyndromal conditions to subthreshold symptoms.
To our knowledge, there are no data on the effect of subthreshold comorbid anxiety on depressive symptoms with respect to treatment outcome.
The primary aim of this study was to evaluate the effect of subthreshold comorbid anxiety, on the clinical presentation and on the response to treatment of depressive disorders.
Methods

Sample
The sample included patients referring to the Centre for the Diagnosis and Treatment of Depressive Disorders at our Department.
Inclusion criteria were : (1) presence of comorbid anxiety and depression at either threshold or subthreshold level; (2) written informed consent. Exclusion criteria were : (1) other comorbid Axis I diagnoses ; (2) previous diagnosis of dysthimia ; (3) Axis II diagnosis ; (4) pregnancy or breastfeeding ; (5) general medical conditions that contra-indicated the administration of psychotropic compounds.
Patients were subdivided in four groups according to the DSM-IV diagnosis : Group 1. Included patients with comorbid MDD and any anxiety disorder (DA).
Group 2. Included patients with comorbid MDD and subthreshold anxiety (anxiety disorder NOS) (Da).
Group 3. Included patients with comorbid subthreshold depression (depressive disorder NOS) and any anxiety disorder (dA).
Group 4. Included patients with comorbid subthreshold depression and subthreshold anxiety (MADD) (da).
Assessment
Diagnoses were assessed by the administration of a semi-structured interview based on DSM-IV criteria (SCID-I). Patient symptom severity was assessed using the Hamilton Rating Scale for Depression (HAMD ; Hamilton, 1960) , the Hamilton Rating Scale for Anxiety (HAMA; Hamilton, 1959) and the Clinical Global Impression Scale (CGI; Guy, 1976) . These rating scales were administered monthly from baseline to the end of the study by trained clinicians blind with respect to the aim of this study. The overall follow-up period was 12 months.
Treatment
Patients received different antidepressants [serotoninselective reuptake inhibitors (SSRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), or serotonin-norepinephrine reuptake inhibitors (SNRIs)] in a naturalistic setting. According to the study design daily doses were flexible and adjusted to the clinical needs of each patient. Benzodiazepines were the only psychotropic compounds allowed for the whole duration of the study. The pharmacological variables across the four groups are summarized in Table 1 . Non-pharmacological treatments were not allowed for any of the patients included in the study.
Statistics
The main baseline demographic and clinical variables were computed for the whole sample and compared across the four groups. Continuous variables were analysed using one-way analysis of variance (ANOVA) with post-hoc comparisons, while categorical variables were analysed using x 2 tests. Qualitative differences in depressive symptoms across the four different diagnostic groups were investigated as follows : each HAMD item score recorded at baseline was transformed into a categorical variable and recorded as absent (score=0) or present (score=1-4).
The effect of psychopharmacological treatment was assessed using ANOVAs with repeated measures, considering HAMD, HAMA and CGI total scores as the dependent variables while diagnostic group and time were the independent ones.
Results
Seventy-eight patient (12 males and 66 females) completed the 12-month follow-up period. The main baseline demographic and clinical variables in the four diagnostic groups are summarized in Table 2 .
Mean daily doses of antidepressants were similar for the four diagnostic groups considered and antidepressant dose ranges were as follows : sertraline The results of the analyses on baseline symptom distribution across the four diagnostic groups are summarized in Table 3 . In the two diagnostic groups ANOVA with repeated measures on HAMD total scores showed a significant time effect (F=55.618, p<0.001), a ' borderline ' group effect (F=2.776, p=0.050) and a significant effect of the interaction between these two factors (F=2.283, p<0.001).
The post-hoc analysis showed that patients with MDD and subthreshold anxiety disorder (Da group) had a lower decrease in depressive symptom severity.
ANOVA with repeated measures on HAMA total scores showed a significant time effect (F=73.843, p<0.000001) and a significant effect of the interaction of group and time (F=3.777, p<0.0001).
ANOVA with repeated measures on CGI total scores (global improvement) showed a significant time effect (F=6.079, p<0.0001). Mean HAMD, HAMA scores over time across the four groups are shown in Table 4 .
The comparison of the percentage of improvement across the four groups did not show significant differences for the HAMD (F=0.077, p>0.9) or for the HAMA (F=1.433, p>0.2).
Discussion
In recent years particular attention has been paid by clinicians to the co-occurrence of depression and anxiety in the same subject and the possible significant clinical implications of this association (Silverstone and Salinas, 2001; Sonawalla et al., 1999) .
The effects of comorbidity between depression and anxiety has been studied in controlled clinical trials, which usually considered anxiety and depression as categories, thus underestimating the importance of subthreshold conditions on the course and on the treatment response. In this study a dimensional approach has been used to study the effect of comorbidity between anxiety and depression considering subthreshold anxiety conditions.
The results from this preliminary naturalistic observation showed that patients with MDD and comorbid anxiety at either full-syndromal or subthreshold level (DA and Da patients) present with significant baseline (i.e. pre-treatment) higher symptom severity. Particularly, these patients presented more frequently suicidal ideation or attempts, psychomotor retardation, sexual dysfunctions, hypochondriacal ideation, weight loss or appetite decrease, and diurnal variation of depressive symptoms.
Some of these clinical features belong to the melancholic subtype of Major Depression and appear to be more frequent in patients with comorbid subthreshold anxiety.
Considering the response to treatment, patients from all diagnostic groups had a significant improvement in symptoms over time. However, patients with Major Depression and subthreshold anxiety had a longer latency of antidepressant response and a lower decrease in symptoms severity.
These results pointing out that patients with MDD and subthreshold anxiety have more severe baseline clinical symptoms, present more frequently with melancholic features, and have an overall worse response to antidepressant treatment have been suggested earlier (Clayton et al., 1991) . It has been reported that depression with psychic and somatic anxiety symptoms may represent a specific subtype resembling 'endogenous ' depression (Clayton et al., 1991) . These patients would have more frequently a positive family history for Major Depression and would have a less favourable course with a longer latency to recovery when treated with antidepressants.
In addition it has been also reported that depressive episodes with ' endogenous' features appear to be less responsive to SSRIs or to novel antidepressants than mild/moderate non-melancholic subtypes (Danish University Antidepressant Group, 1990) .
Some limitations of this study should be considered. First, the study has been done according to a naturalistic design and treatments were not assigned in a randomized, double-blind condition. However, a naturalistic setting has the advantage of being closer to the clinical reality than highly controlled trials where comorbid conditions are usually an exclusion criterion. Second, it may be argued that the inclusion of a group of patients with MDD without comorbid anxiety would have given additional information. However, the primary aim of the study was to investigate the effect on depression of comorbid anxiety considered in a dimensional perspective. Thus, the primary comparison was between patients with MDD and full-syndromal anxiety (DA) and patients with MDD and subthreshold anxiety (Da), while the addition of a group of patients with MDD only would not have added critical information with respect to the aim of the study. Furthermore, there are already several studies published reporting on the comparison between MDD with and MDD without comorbid anxiety. These studies have shown that when depression is associated with anxiety disorders the clinical presentation and the outcome are worse (Altamura et al., 2003; Fawcett, 1990; Van Balkom et al., 2000) .
Finally, the sample studied is small and this may have reduced the power of the analyses performed.
Future studies including larger samples and more controlled pharmacological variables are warranted to confirm these preliminary results and to confirm the impact of comorbid subthreshold anxiety on the clinical presentation and antidepressant response in depressive disorders.
